Research.Patient.info
Indolent Systemic Mastocytosis research hub
2 indexed studies · 1 currently recruiting
- active not recruitingPHASE2
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
This study is testing a new drug called avapritinib for people with a type of mastocytosis called indolent systemic mastocytosis (ISM). It compares avapritinib with a dummy pill (placebo) to see if it helps control symptoms better and is safe.
United States · Belgium · Canada - recruitingPHASE2, PHASE3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
This study is testing a new medicine, elenestinib, for a rare blood condition called indolent systemic mastocytosis. It compares the new medicine to a dummy pill (placebo) to see if it helps reduce symptoms that current treatments aren't fully controlling.
United States · Argentina · Australia